CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900., Gönen, Mithat, Sun Zhuoxin, Figueroa Maria E., Patel Jay P., Abdel-Wahab Omar, Racevskis Janis, Ketterling Rhett P., Fernandez Hugo, Rowe Jacob M., Tallman Martin S., et al. , Blood, 2012 Sep 13, Volume 120, Issue 11, p.2297-306, (2012)

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia., Li, Sheng, Garrett-Bakelman Francine E., Chung Stephen S., Sanders Mathijs A., Hricik Todd, Rapaport Franck, Patel Jay, Dillon Richard, Vijay Priyanka, Brown Anna L., et al. , Nat Med, 2016 Jul, Volume 22, Issue 7, p.792-9, (2016)

DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia., Figueroa, Maria E., Lugthart Sanne, Li Yushan, Erpelinck-Verschueren Claudia, Deng Xutao, Christos Paul J., Schifano Elizabeth, Booth James, van Putten Wim, Skrabanek Lucy, et al. , Cancer Cell, 2010 Jan 19, Volume 17, Issue 1, p.13-27, (2010)

Epigenetics in AML., Melnick, Ari M. , Best Pract Res Clin Haematol, 2010 Dec, Volume 23, Issue 4, p.463-8, (2010)

Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia., Shojaee, Seyedmehdi, Caeser Rebecca, Buchner Maike, Park Eugene, Swaminathan Srividya, Hurtz Christian, Geng Huimin, Chan Lai N., Klemm Lars, Hofmann Wolf-Karsten, et al. , Cancer Cell, 2015 Jul 13, Volume 28, Issue 1, p.114-28, (2015)

General Biomarker Recommendations for Lymphoma., Rimsza, Lisa, Fedoriw Yuri, Staudt Louis M., Melnick Ari, Gascoyne Randy, Crump Michael, Baizer Lawrence, Fu Kai, Hsi Eric, Chan John W. C., et al. , J Natl Cancer Inst, 2016 Dec, Volume 108, Issue 12, (2016)

HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia., Bartholdy, Boris, Christopeit Maximilian, Will Britta, Mo Yongkai, Barreyro Laura, Yu Yiting, Bhagat Tushar D., Okoye-Okafor Ujunwa C., Todorova Tihomira I., Greally John M., et al. , J Clin Invest, 2014 Mar, Volume 124, Issue 3, p.1158-67, (2014)

Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas., Bayliss, Jill, Mukherjee Piali, Lu Chao, Jain Siddhant U., Chung Chan, Martinez Daniel, Sabari Benjamin, Margol Ashley S., Panwalkar Pooja, Parolia Abhijit, et al. , Sci Transl Med, 2016 Nov 23, Volume 8, Issue 366, p.366ra161, (2016)

The many layers of epigenetic dysfunction in B-cell lymphomas., Jiang, Yanwen, Dominguez Pilar M., and Melnick Ari M. , Curr Opin Hematol, 2016 Jul, Volume 23, Issue 4, p.377-84, (2016)

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition., Ennishi, Daisuke, Takata Katsuyoshi, Béguelin Wendy, Duns Gerben, Mottok Anja, Farinha Pedro, Bashashati Ali, Saberi Saeed, Boyle Merrill, Meissner Barbara, et al. , Cancer Discov, 2019 Apr, Volume 9, Issue 4, p.546-563, (2019)

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia., Ribeiro, Ana Flávia Ti, Pratcorona Marta, Erpelinck-Verschueren Claudia, Rockova Veronika, Sanders Mathijs, Abbas Saman, Figueroa Maria E., Zeilemaker Annelieke, Melnick Ari, Löwenberg Bob, et al. , Blood, 2012 Jun 14, Volume 119, Issue 24, p.5824-31, (2012)

Outcome of deferred initial therapy in mantle-cell lymphoma., Martin, Peter, Chadburn Amy, Christos Paul, Weil Karen, Furman Richard R., Ruan Jia, Elstrom Rebecca, Niesvizky Ruben, Ely Scott, Diliberto Maurizio, et al. , J Clin Oncol, 2009 Mar 10, Volume 27, Issue 8, p.1209-13, (2009)

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia., Patel, Jay P., Gönen Mithat, Figueroa Maria E., Fernandez Hugo, Sun Zhuoxin, Racevskis Janis, Van Vlierberghe Pieter, Dolgalev Igor, Thomas Sabrena, Aminova Olga, et al. , N Engl J Med, 2012 Mar 22, Volume 366, Issue 12, p.1079-89, (2012)

Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies., Elstrom, Rebecca L., Martin Peter, Ostrow Katya, Barrientos Jacqueline, Chadburn Amy, Furman Richard, Ruan Jia, Shore Tsiporah, Schuster Michael, Cerchietti Leandro, et al. , Clin Lymphoma Myeloma Leuk, 2010 Jun, Volume 10, Issue 3, p.192-6, (2010)

RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction., Wilkinson, Adam C., Ballabio Erica, Geng Huimin, North Phillip, Tapia Marta, Kerry Jon, Biswas Debabrata, Roeder Robert G., C Allis David, Melnick Ari, et al. , Cell Rep, 2013 Jan 31, Volume 3, Issue 1, p.116-27, (2013)

Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma., Green, Michael R., Vicente-Dueñas Carolina, Romero-Camarero Isabel, Liu Chih Long, Dai Bo, González-Herrero Inés, García-Ramírez Idoia, Alonso-Escudero Esther, Iqbal Javeed, Chan Wing C., et al. , Nat Commun, 2014 Jun 02, Volume 5, p.3904, (2014)

Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes., Chambwe, Nyasha, Kormaksson Matthias, Geng Huimin, De Subhajyoti, Michor Franziska, Johnson Nathalie A., Morin Ryan D., Scott David W., Godley Lucy A., Gascoyne Randy D., et al. , Blood, 2014 Mar 13, Volume 123, Issue 11, p.1699-708, (2014)